MetaCap

Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

515.02-5.64 (-1.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VRTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$130.58B
EPS (TTM)
$15.54
52-week range
412.27 – 568.67
Day range
513.80 – 531.37
Volume / Avg
1.77M / 1.25M
Beta
—

52-week range

$412.27$568.67

VRTX stock today

Shares of Vertex Pharmaceuticals (VRTX) finished lower on Nov 20 at $515.02, a drop of 1.08% or $5.64 per share, versus the S&P 500's 3.70% decline. At this level, VRTX sits in the middle of its 52-week range of $412.27 to $568.67: 9.4% below the high, set on Nov 2, 2026 and 24.9% above the low. VRTX is up 13.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 20.7%.

At 33.1x trailing earnings, Vertex Pharmaceuticals trades above the peer-group median of 20.4x. Its forward P/E of 25.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Vertex Pharmaceuticals

Company profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Reshma Kewalramani FASN, M.D.
Headquarters
Boston, MA
Employees
6,400
IPO year
1991
Website
vrtx.com

Financial highlights

Full financials

In fiscal 2025, Vertex Pharmaceuticals generated $12.00 billion in revenue, up 8.9% from fiscal 2024, its 11th consecutive year of revenue growth. Net income was $3.95 billion, for a net margin of 32.9% versus a median of 36.7% in the prior 5 years. Gross margin was 86.2% (up from 86.1%) and operating margin 34.8%.

Vertex Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$12.00B$11.02B$9.87B$8.93B$7.57B
Growth+8.90%+11.66%+10.51%+17.91%+22.06%
Net income$3.95B$-535.60M$3.62B$3.32B$2.34B
EPS (diluted)$15.32$-2.08$13.89$12.82$9.01

Analyst forecast

Forecast

Consensus (32 analysts)

buy

Avg. price target

$595.36+15.60%

  • Strong buy 6
  • Buy 20
  • Hold 5
  • Sell 1
  • Strong sell 0

Target range

Low $350.00High $725.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$4.22 vs $4.36
Surprise
-3.21%

VRTX news

All VRTX news

Vertex Pharmaceuticals peers

Health Care sector
VRTX peer companies
CompanyPrice% ChgMarket capCompare
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs VRTX
SNYSanofi ADS46.52+1.00%$111.70Bvs VRTX
PFEPfizer Inc.27.40-0.51%$156.18Bvs VRTX
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs VRTX
GSKGSK plc ADR47.76-0.13%$95.73Bvs VRTX
REGNRegeneron Pharmaceuticals Inc.920.69-0.19%$95.24Bvs VRTX
ABTAbbott Laboratories103.00-0.84%$178.39Bvs VRTX
TAKTakeda Pharmaceutical Company Limited ADR21.77+1.68%$69.55Bvs VRTX

Indexes, lists and sector

Vertex Pharmaceuticals stock FAQ

What is Vertex Pharmaceuticals's stock price today?

VRTX last traded at $515.02 as of Nov 20, 4:00 PM EST, down 1.08% on the day. Prices are delayed at least 15 minutes.

Does Vertex Pharmaceuticals pay a dividend?

No. Vertex Pharmaceuticals does not currently pay a regular cash dividend.

What is VRTX's P/E ratio?

VRTX trades at a trailing P/E ratio of 33.14 and a forward P/E of 25.86, compared with a median of 20.4 for its closest peers.

Is Vertex Pharmaceuticals in the S&P 500?

Yes. Vertex Pharmaceuticals (VRTX) is a constituent of the S&P 500 index.

Who is Vertex Pharmaceuticals's CEO?

Dr. Reshma Kewalramani FASN, M.D. is the chief executive officer of Vertex Pharmaceuticals Incorporated, which has about 6,400 employees.

Has VRTX ever split its stock?

Yes. The most recent VRTX stock split was a 2-for-1 split on Aug 24, 2000.

What is the VRTX 52-week high?

The 52-week high for VRTX is $568.67 and the 52-week low is $412.27. The stock is currently 9.4% below its high.

Compare VRTX